Perry Karsen was the Chief Executive Officer of Celgene Cellular Therapeutics from May 2013 until his retirement from Celgene, Corporation at the end of 2015. Perry held the position of Executive Vice President and Chief Operations Officer at Celgene Corporation from July 2010 to May 2013 and he served in various management positions, including Senior Vice President and Head of Worldwide Business Development at Celgene and President of Asia/Pacific Region, from May 2004 until February 2009.
Perry was the President and Chief Executive Officer of Pearl Therapeutics, a privately-held biotechnology company subsequently acquired by Astra- Zeneca, from February 2009 until July 2010. In addition, Perry held executive positions at Human Genome Sciences, Bristol-Myers Squibb, Genentech and Abbott Laboratories earlier in his career. He also was a General Partner at Pequot Ventures from 2000-2003 focusing on investments in biotechnology and medical devices.
Perry has a B.S. in Biological Sciences from the University of Illinois, Urbana, a Master of Arts in Teaching Biology from Duke University, and a Masters of Management from the Kellogg School of Management at Northwestern University. Perry serves on the Board of Directors and as Chair of several private and public biotechnology companies, The Gladstone Foundation, and The Sonoma Land Trust. He is a former member of the Board of Directors and the Executive Committee of the Biotechnology Innovation Organization (BIO) and a past member of the Board of Directors of the Alliance for Regenerative Medicine (ARM).